Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Vandria: renewing mitochondria to treat CNS, muscle and other diseases

Swiss biotech Vandria is restoring energy balance in neurons with its first program, soon to enter the clinic for mild cognitive impairment

March 28, 2024 8:08 PM UTC

Vandria is aiming to restore functional mitochondria in various organs by inducing mitophagy. The result — improved cellular energy production and reduced reactive oxygen species — could be useful for treating a wide range of diseases. 

Vandria S.A. spun out of Amazentis S.A. in 2021 to develop small molecules that induce mitophagy — a process whereby a cell degrades and recycles defective mitochondria, activating the biogenesis of new, healthy ones...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article